BridgeBio Pharma (BBIO) AI Stock Analysis

• Market Cap: $15.01B
• Dividend Yield: N/A
• Average Volume (3M): 1.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 62.46%
• EPS Growth: -73.59%
• Country: US
• Employees: 725
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 192,708,820
• 10 Day Avg. Volume: 2,472,908
• 30 Day Avg. Volume: 1,940,625
• PEG Ratio: 0.35
• Price to Book (P/B): -3.48
• Price to Sales (P/S): 23.01
• P/FCF Ratio: -9.79
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 31.41
• Enterprise Value/Gross Profit: 32.79
• Enterprise Value/Ebitda: -16.41
• 1Y Price Target: $89.25
• Price Target Upside: 14.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): -1.62
• Revenue Forecast (FY): $891.23M

• Rating: 54 Neutral
• Price Target: $75.00 ▼(-3.72% Downside)

BBIO scores in the mid-range: financial performance remains the biggest drag due to losses, negative equity, and declining free cash flow growth, partially offset by strong revenue growth and high gross margin. Sentiment from the latest earnings call is a key positive (Attruby commercial traction and Phase III wins), while technicals are moderately supportive but not strongly trending. Valuation provides limited help given the negative P/E and no dividend yield provided.

Positive Factors

Revenue Growth

The significant revenue growth indicates expanding market reach and successful product adoption, supporting long-term business sustainability.

Successful Phase III Trials

Successful trials enhance the company's pipeline credibility and potential market entry, strengthening its competitive position in the biotech industry.

Strong Financial Position

A robust cash position provides financial flexibility to fund R&D and strategic initiatives, supporting long-term growth and stability.

Negative Factors

High Operating Expenses

Rising operating expenses can pressure margins and profitability, potentially limiting the company's ability to invest in growth opportunities.

Negative Profitability

Persistent negative profitability may hinder long-term financial health and investor confidence, impacting future funding and expansion efforts.

Financial Instability

A weak balance sheet with high leverage poses risks to financial stability, limiting the company's ability to withstand economic downturns.

BridgeBio Pharma Business Overview & Revenue Model

Company Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

How the Company Makes Money

BridgeBio Pharma generates revenue through a combination of product sales, partnerships, and collaborations. The company typically monetizes its drug candidates by advancing them through clinical trials and seeking regulatory approvals, after which they can be commercially launched. Key revenue streams include milestone payments from collaborations with larger pharmaceutical companies, royalties on product sales, and potential licensing agreements. Additionally, significant partnerships with industry leaders can provide upfront payments and shared research funding, contributing to the company’s financial stability and growth.

BridgeBio Pharma Financial Statement Overview

Summary

Strong top-line momentum (TTM revenue up 44.69%) and very high gross margin (96.80%), but overall fundamentals are weighed down by negative profitability, negative stockholders’ equity, and weakening free cash flow growth (-11.53% TTM), signaling elevated financial risk despite growth.

Income Statement

BridgeBio Pharma shows strong revenue growth with a 44.69% increase in TTM, indicating positive momentum. However, the company faces significant challenges with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin remains high at 96.80%, suggesting efficient cost management at the gross level, but overall profitability is hampered by high operating expenses.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity and a high debt-to-equity ratio of -1.50 in TTM, indicating financial instability. Return on equity is positive at 50.71%, but this is due to the negative equity base. The equity ratio is negative, highlighting potential risks in financial health and leverage.

Cash Flow

Cash flow analysis shows a decline in free cash flow growth by -11.53% in TTM, reflecting cash management challenges. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to earnings. However, the free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	353.78M	221.90M	9.30M	77.65M	69.72M	8.25M
Gross Profit	338.84M	218.02M	6.86M	74.21M	66.60M	8.25M
EBITDA	-677.28M	-436.83M	-565.47M	-397.44M	-533.83M	-467.38M
Net Income	-797.12M	-535.76M	-643.20M	-481.18M	-562.54M	-448.72M
Balance Sheet
Total Assets	998.25M	919.34M	546.38M	623.04M	1.01B	703.59M
Cash, Cash Equivalents and Short-Term Investments	645.94M	681.10M	434.88M	471.92M	836.66M	607.09M
Total Debt	1.86B	1.73B	1.74B	1.72B	1.73B	495.79M
Total Liabilities	2.92B	2.38B	1.89B	1.87B	1.88B	595.70M
Stockholders Equity	-1.93B	-1.47B	-1.35B	-1.25B	-870.41M	57.91M
Cash Flow
Free Cash Flow	-595.21M	-521.66M	-529.03M	-425.81M	-546.18M	-407.23M
Operating Cash Flow	-584.82M	-520.73M	-527.72M	-419.49M	-497.93M	-399.71M
Investing Cash Flow	-13.37M	60.78M	54.03M	453.15M	-200.83M	-52.99M
Financing Cash Flow	835.41M	748.46M	451.54M	-13.13M	736.45M	447.19M

BridgeBio Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 77.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 77.9 is above the 20-day moving average (MA) of 75.95, above the 50-day MA of 71.89, and above the 200-day MA of 51.69, indicating a bullish trend. The MACD of 1.42 indicates Positive momentum. The RSI at 54.35 is Neutral, neither overbought nor oversold. The STOCH value of 76.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.

BridgeBio Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	78 Outperform	$12.13B	19.13	30.56%	―	9.93%	54.33%
BMRN	76 Outperform	$10.77B	20.63	9.07%	―	12.31%	60.21%
MDGL	59 Neutral	$11.47B	―	-41.22%	―	864.21%	48.12%
IONS	56 Neutral	$12.77B	-45.12	-39.99%	―	20.39%	34.00%
BBIO	54 Neutral	$15.01B	-18.21	―	―	62.46%	-73.59%
MRNA	53 Neutral	$15.86B	-4.88	-29.32%	―	-56.00%	-38.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BridgeBio Pharma Corporate Events

BridgeBio Showcases Attruby Growth and Pipeline Progress

On January 12, 2026, BridgeBio Pharma used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to highlight strong early commercial traction for Attruby, its ATTR-CM therapy, reporting preliminary unaudited 2025 net product revenue of $362.4 million, supported by 6,629 unique patient prescriptions from 1,632 prescribers, and to announce a new TTR amyloid-depleting antibody program expected to progress to the clinic between 2027 and 2028. The company also reported pivotal data and regulatory momentum across its late-stage pipeline, including a positive interim Phase 3 FORTIFY readout in LGMD2I/R9 that prompted FDA guidance to pursue a traditional full approval pathway and an NDA filing planned for the first half of 2026, an NDA timeline in the same period for encaleret in ADH1 amid rapid growth in diagnosed patients, a planned Phase 3 trial of encaleret in chronic hypoparathyroidism starting in summer 2026, and advancing registrational studies of infigratinib in pediatric achondroplasia and hypochondroplasia, all underpinned by approximately $587.5 million in cash and marketable securities at year-end 2025 to support continued Attruby growth and potential global launches of up to three additional medicines.

The most recent analyst rating on (BBIO) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

BridgeBio Pharma Reports Positive Phase 3 Study Results

BridgeBio Pharma announced positive results from its Phase 3 CALIBRATE study of encaleret for treating autosomal dominant hypocalcemia type 1 (ADH1) on October 29, 2025. The study met all primary and key secondary endpoints, showing significant improvements in calcium and parathyroid hormone levels compared to conventional therapy. Encaleret was well-tolerated, with plans for a New Drug Application submission in 2026. The results suggest encaleret could become a new standard of care for ADH1, potentially impacting the lives of patients with this genetic condition.

The most recent analyst rating on (BBIO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

BridgeBio Pharma Announces Positive Phase 3 Study Results

On October 27, 2025, BridgeBio Pharma announced positive results from its Phase 3 FORTIFY study of BBP-418, a treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The study showed significant improvements in motor and pulmonary functions, with a well-tolerated safety profile, marking a potential breakthrough for a disease with no specific treatments. The company plans to file for FDA approval in the first half of 2026, which could position BBP-418 as the first therapy to alter the course of this debilitating condition.

The most recent analyst rating on (BBIO) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.